Summary & Overview
CPT 78456: Radiolabeled Peptide Platelet Scan for Thrombus Localization
CPT code 78456 represents a nuclear medicine diagnostic procedure in which a peptide labeled with a gamma-emitting radionuclide is mixed and injected to identify the location of thrombi and to track platelets. This imaging technique is clinically important for evaluating suspected thrombotic disease when planar or tomographic visualization of platelet deposition can inform diagnosis or management. Nationally, use of this procedure impacts resource allocation in nuclear medicine services and intersects with payer coverage policies for advanced diagnostic imaging.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of payer coverage trends, common billing modifiers associated with advanced imaging services, and clinical context that supports appropriate use. Readers will find benchmarks for coding and billing practice, explanations of the clinical purpose of the study, typical sites of service, and a summary of common modifiers used with this type of procedure. Data not available in the input is noted where applicable.
This summary is intended for billing managers, radiopharmacy and nuclear medicine clinicians, and policy analysts seeking a concise reference for CPT code 78456 and its role in thrombus localization imaging.
Billing Code Overview
CPT code 78456 describes a diagnostic nuclear medicine procedure in which a peptide labeled with a gamma-emitting radionuclide is prepared and injected to localize thrombi and track platelets. This procedure is used to determine the site of clots and visualize platelet distribution.
-
Service type: Nuclear medicine diagnostic imaging with radiolabeled peptide for thrombus localization
-
Typical site of service: Hospital outpatient department, nuclear medicine department, or specialized imaging center
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of atrial fibrillation and recent hip replacement presents with acute unilateral leg swelling and pain suspicious for deep vein thrombosis (DVT). Noninvasive ultrasound is inconclusive because of extensive edema and prior surgical changes. Nuclear medicine is consulted to perform a platelet scintigraphy study using autologous platelets labeled with a gamma-emitting radionuclide to localize active thrombi and evaluate for thrombus propagation or embolic sources. The workflow includes blood draw and separation of platelets, radiolabeling the platelets with the peptide-radionuclide conjugate, quality control checks, intravenous injection of the radiolabeled platelets, and serial gamma imaging over several hours to identify sites of increased uptake corresponding to clot. The imaging report documents the time-activity pattern, location and extent of focal uptake, comparison with prior imaging when available, and implications for anticoagulation management or interventional planning. Typical site of service is an outpatient nuclear medicine department, hospital-based radiology/nuclear medicine suite, or ambulatory imaging center. Patient preparation includes medication reconciliation for anticoagulants, explanation of the procedure and radioactive exposure, venous access placement, and monitoring for immediate adverse reaction during and after injection.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing physician or nuclear medicine physician reports interpretation and report separate from facility technical component. |